A new treatment, used successfully in Europe, is making its way to the United States and is showing promising results for those suffering with back pain.
After a recent car accident, tire company owner Lindsey Clark suffered from severe back pain that kept him from doing his job.
“I couldn’t walk, couldn’t come to work, couldn’t find […]
CAMBRIDGE, UK | Feb 19, 2007 | CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company today announces preliminary results of the pivotal Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. This study is the largest carried out to date with M6G and has delivered very strong results. […]
Now that it has gained more than a year’s experience with radio frequency identification, Pfizer is preparing its first electronic pedigree (e-pedigree) trial for a launch this year. The trial will document the movement of individually tagged bottles of Viagra as they leave Pfizer’s facilities for delivery to distributors, wholesalers and other partners. Favored by […]
ROCKFORD — The research arm of a local doctors’ group is looking for people with aching joints and heart troubles for a clinical study.
Rockford Health Physicians wants arthritis sufferers to join a massive international study of the effectiveness and safety of several popular pain relievers in light of recent evidence that some increase the risk […]
Among patients treated with the FOLFOX7 chemotherapy regimen for metastatic colorectal cancer, the addition of Celebrex® (celecoxib) did not further improve outcomes. These results were published in Annals of Oncology.
Colorectal cancer is the second leading cause of cancer-related deaths in the United States. The disease develops in the large intestine, which includes the colon (the […]
THE gastrointestinal tract is quite amazing. Measuring about 23ft from the lips to the anus, it’s responsible for the digestion and absorption of the food we take in – everything that we eat has to pass through this organ.
Essentially we are what we eat; and absorb. But inadequate or faulty digestive processes can […]
NEW YORK (Reuters Health) - A large study confirms that Vioxx (rofecoxib), but not Celebrex (celecoxib), is associated with increased risk of a first heart attack. However, people with a prior heart attack may be at increased risk for experiencing another if they use either selective COX-2 inhibitor, the research indicates.
While Vioxx was pulled from […]